EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Voyager Therapeutics, Inc. (VYGR) had EBIT Margin of -326.56% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$40.37M |
|
$-119.72M |
|
-- |
|
$40.37M |
|
$172.22M |
|
$-131.84M |
|
$12.27M |
|
$-119.58M |
|
$-119.58M |
|
$-119.72M |
|
$-119.72M |
|
$-119.72M |
|
$-119.72M |
|
$-131.84M |
|
$-130.76M |
|
58.69M |
|
58.69M |
|
$-2.04 |
|
$-2.04 |
|
| Balance Sheet Financials | |
$202.69M |
|
$13.14M |
|
$49.59M |
|
$252.28M |
|
$26.54M |
|
-- |
|
$29.66M |
|
$56.20M |
|
$196.08M |
|
$196.08M |
|
$196.08M |
|
59.05M |
|
| Cash Flow Statement Financials | |
$-132.47M |
|
$125.45M |
|
$0.82M |
|
$74.24M |
|
$68.04M |
|
$-6.21M |
|
$14.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.64 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-326.56% |
|
|
EBIT Margin |
-326.56% |
-323.86% |
|
-296.17% |
|
-296.53% |
|
$-135.06M |
|
-- |
|
-- |
|
-- |
|
0.16 |
|
-- |
|
21.12 |
|
17.29 |
|
-61.06% |
|
-61.06% |
|
-47.46% |
|
-61.06% |
|
$3.32 |
|
$-2.30 |
|
$-2.26 |
|